• Botanix raises $40 million via institutional placement
• Funds to accelerate Sofdra commercialization in the US
• Strong early sales performance, with over 500 new patients per week

Botanix Pharmaceuticals has received firm commitments for a $40 million capital raising via a strongly supported institutional placement. The proceeds will be used to fund an expansion of the sales force and infrastructure, widening the digital platform and marketing activities, inventory and logistics, platform expansion and additions, operating costs and general administrative expenses, as well as costs of the placement. The placement follows the completion of the first quarter of Sofdra sales with the full sales force, which has produced strong results. New patient arrivals are now trending to more than 500 a week, at a run rate of over 2,000 per month. Individual prescriber numbers are now exceeding 400 per week and more than 1,500 prescribers have written Sofdra prescriptions since the sales force launched. Refills in March 2025 reached 100% of eligible patients.Based on the early performance of Sofdra, the company now believes there is significant upside to the commercialization potential of the product, justifying an earlier investment in expansion than originally planned. The funds will be used to accelerate sales, marketing and support activities to continue growing new patient arrivals.

The company expects to see continued strong growth in new patient arrivals, prescriber numbers, and refill rates for Sofdra in the coming quarters.

Botanix is confident that the additional investment will allow it to accelerate the commercialization of Sofdra and capitalize on the significant potential of the product.